22OCT

Stryker takes option to buy CMR Surgical

3 min read

16:30UTC

Stryker is putting about $400m of preferred equity into Cambridge's CMR Surgical and taking an exclusive option to buy the whole company.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Stryker's option makes a sale, not a flotation, CMR Surgical's likeliest exit.

Stryker agreed on Monday 12 October to put about $400m (about £300m) of preferred equity into CMR Surgical, the Cambridge maker of the Versius surgical robot. Preferred equity is a class of shares that normally ranks ahead of ordinary shares on a sale. Stryker said it will also receive an exclusive option to buy 100% of the company, the right but not the duty to take the rest later⁠¹.

Neither side disclosed an exercise price or a timetable. On these terms, CMR Surgical's likeliest exit is Stryker exercising its option, not a flotation. Stryker also becomes the exclusive US sales agent for Versius, while CMR Surgical keeps product development and sales outside the United States in Cambridge. Closing needs regulatory approvals that the announcement does not list.

Stryker's 12 October announcement said its Medsurg group president Andy Pierce was expected to join the CMR Surgical board. Stryker calls the deal its entry into soft-tissue robotics, beyond the Mako orthopaedic robot it already sells. In July, Bosch and Schaeffler took equity in Humanoid alongside commercial orders; Stryker's terms add distribution rights and a path to owning the whole company.

Deep Analysis

In plain English

CMR Surgical is a Cambridge company that makes Versius, a robot that helps surgeons carry out keyhole operations through small cuts. Stryker is a large American medical-equipment firm. It is putting about $400m into CMR Surgical. In return it gets the sole right to sell Versius in the United States and the right, but not the duty, to buy the whole company later at a price neither side has published. For British readers, the question is whether one of the country's best-known medical-technology firms stays independent or becomes part of an American group.

Deep Analysis

Root Causes

Surgical robots need a large installed base before recurring revenue from instruments covers the cost of each system. In the United States, Intuitive Surgical's da Vinci holds that installed base, so a challenger needs a hospital sales force on the same scale. Stryker already sells the Mako orthopaedic robot into American operating theatres; CMR Surgical does not have an equivalent channel.

Preferred equity matters here. It normally ranks ahead of ordinary shares in a sale, so on standard terms Stryker's money is better protected than earlier ordinary holders' if the option is never exercised. Stryker and CMR Surgical have not published the preference terms.

What could happen next?

Consequence
Stryker's exclusive option makes a competing offer for CMR Surgical unlikely while the option stands.
Medium term · Assessed
Risk
Regulatory approvals are unlisted; a UK National Security and Investment Act review is possible but not confirmed.
Short term · Suggested
Precedent
A minority stake with an option on 100% gives foreign acquirers a template for buying British medical hardware in stages.
Long term · Suggested

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Medtronic took an equity stake in the Israeli spine-robot maker Mazor Robotics in 2016 alongside exclusive distribution rights, then bought the whole company in 2018 for about $1.6bn. The sequence ran distribution first, then minority equity, then purchase: the same order Stryker has now written into a single agreement.

Counter-parallel: Roche paid $2.1bn for 60% of Genentech in 1990 with an option on the rest, yet took full ownership only in 2009, for $46.8bn. An option holder can wait for decades, and the price of waiting rises with the company's success.

The immediate effect is cash and a US channel: about $400m of preferred equity, reported by MassDevice from Stryker's announcement, and exclusive American distribution of Versius.

The structural effect falls on price discovery. An exclusive option deters rival bidders, because any rival must outbid a shareholder that already holds US sales rights and a board seat shows Bank of America buying MDSec in August, the same direction of travel for British specialist firms. Until the exercise price is published, outside investors cannot value CMR Surgical's remaining equity with confidence.

Consensus view: MassDevice and Modern Healthcare read Stryker's own announcement as a staged acquisition: Stryker calls the deal its entry into soft-tissue robotics, and an exclusive option over 100% of the equity gives it control of CMR Surgical's endgame without paying a takeover premium today.

Counter-view: Empirical Ventures co-founder Ben Miles argued in City AM on 5 October that heavier taxes on startup success push British spinouts to sell early to foreign buyers; on that reading the option reflects UK exit conditions as much as Stryker's strategy.

Key tension: Whether an undisclosed exercise price lets CMR Surgical's other shareholders test the market later, or fixes the company's value before Versius has proved itself in American hospitals.

Sources:MassDevice

Mentions:Stryker Corporation →CMR Surgical →Versius →Mako →Cambridge →United States →Humanoid →Schaeffler →Bosch →City AM →Andy Pierce →National Security and Investment Act →Bank of America →MDSec Consulting →NHS →

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

MassDevice· 22 Oct 2026

Read original →

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.